The compound is a long-acting analog of amylin & it has demonstrated significant weight loss in preclinical models of obesity.
The research will be conducted in Germany & funded by Boehringer Ingelheim, by results Guessed in late 2018.
[i]Adam Steensberg, Executive Vice President, Chief Medical & Development Officer of Zealand, comments: “We are proud that Boehringer Ingelheim has chosen to move these two novel analogs forward to Phase 1.
We have a strong partnership by Boehringer Ingelheim & look forward to future researches that will establish if the impressive preclinical weight loss results can be confirmed in clinical trials.”
Zealand has two collaborations by Boehringer Ingelheim, & under the terms of the two licences Boehringer Ingelheim funds all research, development & commercialization activities.
as informed in
Zealand Pharma collaboration partner Boehringer Ingelheim launches early-stage researches of diabetes & fatness candidates
Zealand Pharma A/S (ZEAL +0.5% ) announces that development partner, privately held Boehringer Ingelheim, has initiated Phase one researches assessing candidates for the curing of obesity and/or diabetes.
The company tells portion of its therapeutic action is based on the natural gut hormone oxytomodulin, that reliefs food intake & increases energy use.
The estimated primary completion date is June 2018.
Another Phase one will assess BI 473494, a long-acting amylin analog, for the curing of obesity and/or diabetes.
Its primary completion date is also June 2018.
as informed in Research led by the University of Birmingham, published today in Science Translational Medicine, has disclosed that a drug commonly used to treat patients by either obesity or Type II diabetes can be used as a novel Fresh way to reduce brain pressure.
Raised brain Stress is common in emergency situations like traumatic brain injury, hydrocephalus & stroke, & is also the cardinal feature of Idiopathic Intracranial Hypertension (IIH).
IHH causes disabling daily headaches & severely lifted Stress around the nerves in the eye.
They are also potentially game-changing for other conditions featuring lifted brain pressure, including stroke, hydrocephalus & traumatic brain injury.
The University of Birmingham is This time due to begin a clinical experience to test GLP-1 agonist drug in patients by lifted brain pressure.
This content may collect you by Sydney Connor